Product Information
ATOVAQUONE-PROGUANIL 250-100 MG TABLET is a generic product labeled by BluePoint Laboratories, priced at $1.4858 per EA under NDC 68001024500. Its NADAC has been published 648 times since May 7, 2014.
FDA first approved this application on Jan 12, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250; 100 mg/1; mg/1
Manufacturer
BluePoint LaboratoriesNDC
68001024500
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATOVAQUONE; PROGUANIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091211FDA Approved
1/12/2011
TE Code
AB
On Market Since
3/13/2014
Pharmacological Classes
Price Statistics
The NADAC for ATOVAQUONE-PROGUANIL 250-100 MG TABLET has been published 648 times since May 7, 2014, and over the history we have for it it has declined 71.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4858 per EA |
|---|---|
| All-time high | $5.4053 (Jun 10, 2015) |
| All-time low | $1.2534 (Nov 20, 2024) |
| 52-week high | $1.7306 |
| 52-week low | $1.4777 |
| Median price | $2.6554 |
| Average price | $3.0047 |
| Largest weekly change | +67.1% (Feb 22, 2023) |
| Weeks tracked | 648 |
| Tracking since | May 7, 2014 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
BluePoint Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atovaquone and Proguanil Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimalarial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATOVAQUONE-PROGUANIL 250-100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ATOVAQUONE-PROGUANIL 250-100 MG TABLET, manufactured by BluePoint Laboratories, is $1.4858 per EA (NDC 68001024500), effective Sep 30, 2026.
How has the price of ATOVAQUONE-PROGUANIL 250-100 MG TABLET changed over time?
Over the history we have for it, the NADAC for ATOVAQUONE-PROGUANIL 250-100 MG TABLET has declined 71.9%. It has been tracked across 648 weekly CMS publications since May 7, 2014.
What are the highest and lowest recorded NADAC prices for ATOVAQUONE-PROGUANIL 250-100 MG TABLET?
Since May 7, 2014, the NADAC for ATOVAQUONE-PROGUANIL 250-100 MG TABLET has ranged from a low of $1.2534 (Nov 20, 2024) to a high of $5.4053 (Jun 10, 2015), with a median of $2.6554 per EA.
Are there cheaper alternatives to ATOVAQUONE-PROGUANIL 250-100 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ATOVAQUONE-PROGUANIL 250-100 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ATOVAQUONE-PROGUANIL 250-100 MG TABLET?
ATOVAQUONE-PROGUANIL 250-100 MG TABLET (NDC 68001024500) is labeled by BluePoint Laboratories, and CMS classifies it as a generic product.